title: Subcutaneous Immunoglobulin in Oncology Clinical Practice.
abstract: The administration of gammaglobulin as replacement therapy to boost immune function in patients with immunodeficiency secondary to malignancy is traditionally given in the IV formulation. A pilot program at a large Canadian cancer center led by an advanced practice nurse (APN) demonstrated that transitioning patients to home-based, self-administered subcutaneous infusions (subcutaneous immunoglobulin [SCIG]) led to savings and benefits for patients and the institution. The implementation of SCIG in oncology by an APN is a novel and innovative patient-centered approach to supportive care.
authors.affiliation: CancerCare Manitoba, Winnipeg, Canada.
authors.forename: Erin
authors.initials: E
authors.lastname: Streu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002170:Canada; D005260:Female; D006699:Home Care Services; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000276:immunology*; D055104:Infusions, Subcutaneous / Q000379:methods; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D012646:Self Administration / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous
keywords: evidence-based practice; leukemia/lymphoma; supportive care